Abstract
Treatment aimed at correcting a specific gene mutation is a completely new approach for CF patients, which is mainly based on the so-called cystic fibrosis protein modulators (CFTR-modulators). These medications have been administered since the end of 2019 to CF patients in Bulgaria as well. Particular attention is directed to liver function in patients on CFTRm, as this may be the limiting factor for these medications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Paper Title
Journal
Date
